Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by rhabdomyolysis. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by a hemolytic reaction. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by an iodinated contrast medium. In this invention, vitamin B12 or a pharmaceutically acceptable salt thereof is used.

Abstract: In the present invention, particular compounds such as pyrosulfurous acid and inert gas are used for the purpose of enhancing the stability of a liquid formulation comprising cilastatin.

Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by an iodinated contrast medium. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by an iodinated contrast medium. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

Abstract: The present invention relates to a method of estimating the number of urinary podocytes, including detecting podocalyxin in a urinary sediment sample liquid, and more specifically, to a method of estimating the number of urinary podocytes, including the following steps (1) to (3): (1) a step of preparing the urinary sediment sample liquid by separating urinary sediment from urine collected from a test subject and solubilizing podocalyxin in the urinary sediment; (2) a step of calculating a podocalyxin excretion amount in the urinary sediment sample liquid through detection of podocalyxin in the urinary sediment sample liquid; and (3) a step of calculating the number of urinary podocytes by dividing the podocalyxin excretion amount in the urinary sediment sample liquid by a podocalyxin amount per podocyte.

Abstract: A specimen extraction kit includes a flexible tubular container configured to contain an extraction liquid, two holding portions opposed to each other and arranged at opposite sides of the tubular container, a coupling portion that couples the opposing holding portions, and a bending rib arranged on each of the opposing holding portions and configured to bend the tubular container and an extraction subject.

Abstract: The present invention relates to a method of estimating the number of urinary podocytes, including detecting podocalyxin in a urinary sediment sample liquid, and more specifically, to a method of estimating the number of urinary podocytes, including the following steps (1) to (3): (1) a step of preparing the urinary sediment sample liquid by separating urinary sediment from urine collected from a test subject and solubilizing podocalyxin in the urinary sediment; (2) a step of calculating a podocalyxin excretion amount in the urinary sediment sample liquid through detection of podocalyxin in the urinary sediment sample liquid; and (3) a step of calculating the number of urinary podocytes by dividing the podocalyxin excretion amount in the urinary sediment sample liquid by a podocalyxin amount per podocyte.

Abstract: A specimen extraction kit includes a flexible tubular container configured to contain an extraction liquid, two holding portions opposed to each other and arranged at opposite sides of the tubular container, a coupling portion that couples the opposing holding portions, and a bending rib arranged on each of the opposing holding portions and configured to bend the tubular container and an extraction subject.

Abstract: Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.

Abstract: Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.

Abstract: An object of the present invention is to provide a method for increasing the sensitivity of an immunoassay system. In order to achieve the object, the present inventors have discovered that the sensitivity of an immunoassay system can be increased by pretreating urine and thus have completed the present invention.

Abstract: The object of the present invention is to provide a method for estimating the glomerular renal function in a convenient and non-invasive manner. As a result of intensive studies to achieve the above object, the present inventors found that there is a high correlation between the urinary megalin excretion rate and the estimated glomerular filtration rate (eGFR) in renal disease patients, and the glomerular filtration rate (GFR) can be estimated with high probability in a non-invasive manner by measuring the megalin level in the urine. This has led to the completion of the present invention.

Abstract: An object of the present invention is to provide a method for increasing the sensitivity of an immunoassay system. In order to achieve the object, the present inventors have discovered that the sensitivity of an immunoassay system can be increased by pretreating urine and thus have completed the present invention.

Abstract: The present invention relates to a method of detecting urinary podocytes with a light microscope through use of an insoluble carrier-bound antibody that recognizes a protein specifically expressed on a podocyte surface, and more specifically, to a method of detecting urinary podocytes, including the following steps of (1) to (3) : (1) preparing an insoluble carrier-bound antibody by binding an insoluble carrier to an antibody that recognizes a protein specifically expressed on a podocyte surface; (2) bringing a urine sample of a test subject into contact with the insoluble carrier-bound antibody; and (3) observing the urine sample brought into contact with the insoluble carrier-bound antibody with a light microscope to count podocytes.

Abstract: The object of the present invention is to provide a method for estimating the glomerular renal function in a convenient and non-invasive manner. As a result of intensive studies to achieve the above object, the present inventors found that there is a high correlation between the urinary megalin excretion rate and the estimated glomerular filtration rate (eGFR) in renal disease patients, and the glomerular filtration rate (GFR) can be estimated with high probability in a non-invasive manner by measuring the megalin level in the urine. This has led to the completion of the present invention.

Abstract: An object of the present invention is to provide a method for increasing the sensitivity of an immunoassay system. In order to achieve the object, the present inventors have discovered that the sensitivity of an immunoassay system can be increased by pretreating urine and thus have completed the present invention.

Abstract: Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.

Abstract: This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.